Summary of "What's New and Different in the Surviving Sepsis Campaign 2026"
High-level summary
- This session reviewed the methodology used to produce the 2026 Surviving Sepsis Campaign (SSC) adult guideline and highlighted what is new or changed versus prior iterations, including considerations for low‑ and middle‑income countries (LMICs).
- The 2026 guideline is comprehensive (129 statements), developed by a large, geographically and disciplinarily diverse panel, and uses modern, transparent guideline methods (GRADE, evidence‑to‑decision tables, formal conflict‑of‑interest management).
- Many recommendations are conditional, reflecting limited or heterogeneous evidence. LMIC applicability was explicitly considered and LMIC‑experienced panelists were included.
Methodology and how recommendations were developed (stepwise)
Organization and panel composition
- Leadership team: chairs/co‑chairs, methods lead, COI leads, LMIC leads.
- Guideline working groups: six subgroups, a dedicated systematic review team, and patient/family representatives.
- Panel: ~69 panelists from 23 countries, with substantial LMIC representation (~38% current or prior LMIC practice) and multi‑specialty representation.
Conflicts of interest (COI)
- Rigorous declaration and adjudication process for financial and intellectual COI.
- Individuals with intellectual COI (e.g., who led relevant trials) could participate in discussions but were excluded from voting on related PICO questions.
Question and outcome selection
- Clinical questions framed in PICO format.
- Questions chosen based on clinical importance, gaps in practice, prior coverage, and subgroup prioritization with leadership approval.
- Outcomes were generated and prioritized using GRADE; only patient‑critical outcomes were retained.
Evidence search and synthesis
- New PICOs: full, unrestricted literature searches.
- Updated PICOs: searches began from the last guideline search date.
- When trustworthy, existing guideline searches were adapted/updated.
- Evidence summarized via meta‑analysis: used high‑quality existing systematic reviews where available; otherwise, de novo meta‑analyses were performed.
Certainty of evidence (GRADE)
- Standard GRADE approach: RCT evidence starts high and may be downgraded for bias, indirectness, inconsistency, etc.; observational evidence starts low and may (rarely) be upgraded for very large effects.
- New systematic use of minimally important difference (MID) thresholds for each critical outcome (derived from a panel survey) to inform judgments about effect magnitude.
Evidence‑to‑Decision (EtD) framework
- Considered desirable/undesirable effects, certainty of evidence, patient values/preferences, resources/cost‑effectiveness, equity, acceptability, and feasibility.
- EtD tables and rationale are provided in the guideline supplement.
Panel discussion and voting
- Recommendations were voted on by non‑conflicted full panel members.
- Minimum response rates and thresholds for agreement were required; multiple voting rounds were permitted (typically up to three).
- Carryover statements (from prior guidelines where change was unlikely) were reviewed and received a one‑round vote to conserve resources.
Types of statements used
- Strong recommendations: “We recommend…” (generally higher certainty or clear balance of effects).
- Conditional recommendations: “We suggest…” (formerly “weak”).
- Good practice statements (formerly “best practice”).
- “In our practice” statements — descriptive, not graded, not formal recommendations; used to show practice variability and generate hypotheses.
- Statements of insufficient evidence — explicitly flagged as research priorities.
Key facts about the 2026 guideline
- Total statements: 129
- Majority conditional: approximately 64–68% conditional
- Strong recommendations: 17
- Good practice statements: 19
- Statements of insufficient evidence (research priorities): 11
- New questions addressed in 2026: 46 statements
- Panel demographics: 69 panelists from 23 countries; ~38% with LMIC experience; ~35% from outside Europe/North America
Major clinical recommendations and practical takeaways (by domain)
Screening / pre‑hospital care
- Suggest using a standard sepsis screening tool for acutely ill patients en route to hospital (ambulance/flight).
- For adults with definite/probable sepsis and hypotension with prolonged transport (≈ >1 hour expected without in‑hospital evaluation): suggest initiating antimicrobials pre‑hospital — only after a structured pre‑hospital sepsis screening is in place; this is targeted, not universal.
- Recommend implementing code‑sepsis/sepsis‑huddle protocols (multidisciplinary rapid‑response processes) where feasible.
Antimicrobial therapy
- Timing
- For definite/probable sepsis, especially septic shock: give antimicrobials promptly.
- If sepsis is only possible and shock is absent: antibiotics may be delayed safely up to ≈3 hours (per remarks).
- Empiric anti‑anaerobic coverage
- Conditional pair of statements: suggest empiric anaerobic coverage for patients at high risk for anaerobic infection; suggest minimizing/withholding anaerobic coverage when risk is low (avoid unnecessary metronidazole/clindamycin; note that some agents, e.g., piperacillin‑tazobactam, include anaerobic activity).
- De‑escalation
- Upgraded to a strong recommendation: discontinue unnecessary antibiotics once susceptibilities and source are known.
- Empiric antifungal therapy
- Conditional recommendation against routine use; judicious empiric use may be appropriate for high‑risk patients (immunosuppressed, prolonged antibiotics/hospitalization, intra‑abdominal infections).
- Prolonged infusion beta‑lactams
- Prolonged (extended/continuous) infusion for maintenance is recommended (upgraded to strong vs. bolus dosing).
Microbiology / cultures
- Strong recommendation: obtain blood cultures for possible/probable/definite septic shock as soon as feasible and ideally before antibiotics.
- LMIC guidance: one set (one site) of blood cultures with adequate volume (e.g., ≈10 mL) is acceptable when resources are limited; anaerobic bottles not routinely required unless specifically suspected.
- Specific advice provided on repeat cultures (e.g., for S. aureus, Candida) and appropriate site‑specific sampling.
Hemodynamic management, fluids, vasopressors
- Mean arterial pressure (MAP)
- Recommend targeting MAP ≈60 mmHg (rather than higher targets); a practical range (± ≈5 mmHg) is advised.
- For older patients (≥65): suggest a lower MAP target range (60–65 mmHg) to reduce vasopressor exposure.
- Fluid resuscitation
- Suggest initial 30 mL/kg crystalloid within the first 3 hours for sepsis‑induced hypoperfusion/septic shock — emphasize individualization to avoid over‑ or under‑resuscitation; use actual or adjusted/ideal body weight for dosing in obesity.
- Use balanced crystalloids (e.g., Ringer’s lactate) for resuscitation.
- After acute resuscitation, suggest active fluid removal (diuretics/ultrafiltration as clinically indicated) to avoid fluid overload and achieve neutral balance.
- Guiding further fluid boluses: use dynamic tests of fluid responsiveness (e.g., passive leg raise, pulse pressure variation) and trending lactate or capillary refill time.
- Vasopressors
- Norepinephrine is first‑line.
- Add vasopressin when high norepinephrine doses are required.
- Angiotensin II may be used (very low‑certainty evidence).
- Dobutamine for myocardial dysfunction/cardiac failure.
- Peripheral vasopressor administration is acceptable when central access is unavailable (important practical remark for LMICs).
Monitoring
- Either invasive or non‑invasive blood pressure monitoring is suggested (conditional; very low certainty); invasive monitoring may be useful with high vasopressor doses, frequent ABGs, or discrepant readings.
- Lactate measurement is recommended; if lactate is unavailable, capillary refill time is an acceptable pragmatic alternative or adjunct to guide resuscitation.
- Pulse oximetry and SpO2/FiO2 ratios are acceptable surrogates for PaO2/FiO2 when arterial blood gases are not available.
Respiratory management
- Awake (non‑intubated) proning for hypoxemic patients is supported based on COVID‑era evidence (practical, low‑cost intervention).
- Standard mechanical ventilation principles apply; the guideline contains additional specific respiratory statements.
- For mechanically ventilated patients, suggest selective digestive decontamination (SDD): evidence shows mortality reduction and possible reduction in multidrug resistance. SDD typically involves topical oropharyngeal agents plus targeted IV antibiotics focused on gram‑negatives.
Adjunctive therapies
- Intravenous corticosteroids: meta‑analysis indicates mortality reduction with short courses; guidance is provided.
- Stress ulcer prophylaxis: PPIs recommended for patients at high risk of major GI bleeding; H2 blockers are acceptable alternatives.
- Antipyretics: suggest against routine use to improve clinical outcomes; may be used for symptom control or special situations (e.g., neurocritical care).
Source control
- Timely source control (e.g., drainage, surgery) is emphasized; earlier is generally better. The guideline gives a practical target (e.g., within 6 hours when feasible) while stressing clinical judgment.
Transitions of care and long‑term outcomes
- Good practice statements: educate primary care providers and support critical‑illness follow‑up services and rehabilitation.
- Authors acknowledge variability in LMIC capacity but recommend aspiration and advocacy for these services.
Research priorities / insufficient evidence
- Eleven statements were identified as having insufficient evidence and are listed as priorities for future research.
LMIC applicability and practical adaptations emphasized
- The guideline explicitly considered LMIC contexts through:
- Inclusion of LMIC‑experienced panelists and endorsements from many regional societies.
- Pragmatic recommendations: use capillary refill when lactate is unavailable; non‑invasive BP monitoring acceptable; epinephrine as an alternative if norepinephrine is unavailable; one set of blood cultures acceptable when resources are limited; peripheral vasopressors allowed.
- Emphasis on clinical acumen, focused/basic high‑impact interventions, and adaptable recommendations rather than one‑size‑fits‑all guidance.
- The presenters stressed that resource constraints do not justify low quality care; simple, well‑performed interventions can yield major benefit.
Resource constraints do not justify low quality care — simple, well‑performed interventions can yield major benefit.
Other notable points and context
- Carryover statements: 44 statements from prior guidelines were carried over after panel review, allowing focus on new questions.
- Transparency: detailed EtD tables and methods are available in the guideline supplement so readers can see the basis for each recommendation.
- Some recommendations were upgraded since 2021 (e.g., prolonged beta‑lactam infusion and antibiotic de‑escalation are now strong).
- The panel highlighted a moral/ethical imperative to make sepsis care equitable and practical across settings, citing public health and humanitarian perspectives.
Speakers / sources featured
- Craig Coopersmith — moderator (introduced session)
- Daniel De Backer — co‑chair/moderator
- Walid Al Hazani (presented methodology) — methodological chair for the 2026 adult SSC (auto‑captions may have misspelled the name; commonly cited methods chair is Walid Alhazzani)
- Morten Hylander Møller — methods co‑lead
- Hallie Prescott — co‑chair representing SCCM (name appears variably in captions)
- Massimo Antonelli — co‑chair representing ESICM; presented changes since 2021 and hemodynamic guidance
- Mervyn Mayer — speaker focused on LMIC applicability (name appears as such in captions)
- Patient and family representatives — acknowledged contributors (unnamed)
- Additional referenced persons/works and multiple endorsing societies (25 endorsing societies noted)
Additional outputs noted in the session
- A one‑page quick reference (single‑page checklist) of the most actionable bedside recommendations for clinicians can be derived from the guideline.
- Extraction and listing of all new/changed PICO topics with the exact recommendation text and level of evidence are available in the guideline supplement.
Category
Educational
Share this summary
Is the summary off?
If you think the summary is inaccurate, you can reprocess it with the latest model.
Preparing reprocess...